Fortunately, most of the CHIP-derived mutant/variant genes are not currently actionable for solid tumour, although a JAK2 inhibitor (fedratinib) has been approved by the US FDA for the treatment of the rare bone marrow disease, myelofibrosis. This evidence concerns the gene JAK2 and bone marrow disorder.